- No strong opportunity cluster is confirmed yet; monitor trend and activity pressure.
CYC
ASX
Week ended 24 Jul 2026
Weekly Investor Report
Cyclopharm Limited · Healthcare · Medical Distribution
Latest close
0.56 AUD
-6.7%
latest week
Weekly setup
Mixed setup
The weekly trend is not active. Price is -26.1% below the Trend Line and sits at 13.1% of its 52-week range. The latest completed week returned -6.7%, after a 12.0% four-week move. The latest factor snapshot indicates quality ranks weakly versus its universe; growth ranks weakly; valuation is expensive relative to peers. The latest news-sentiment score is 56/100. Near-term considerations: volume confirmation is below normal.
Setup score
19
out of 100
Latest Close
0.56 AUD
24 Jul 2026
1W Return
-6.7%
latest completed week
4W Return
12.0%
short-term follow-through
12W Return
-22.8%
quarterly tape
Trend Breadth
3.8%
2 of 52 weeks active
Volume Ratio
0.3x
vs 13-week average
- The trend backdrop is inactive, so price action has not confirmed a constructive regime.
- Price is below the Trend Line, which keeps downside pressure in focus.
- Price is below Fair Value, so the market is still discounting the latest tape.
- Activity pressure is negative, which weakens the current setup.
- Trend Line remains the key weekly regime level.
- Activity pressure is the gauge to monitor for confirmation or fade.
- A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through
-6.7%
Latest completed week; four-week move 12.0%.
Indicator stack
2/31
Trend and activity pressure are weighted against the latest 12-week confirmation window.
Trend backdrop
Active
The trend backdrop defines the current weekly regime.
Patient Capital
Quiet
Activity-pressure buy-signal status for institutional accumulation timing.
Next-Week Expectancy
Negative 41.68%
Historical one-week expectancy contributes to the evidence score when direction is confirmed.
News sentiment
56/100
19 relevant articles in the latest sentiment read.
01 · Price action
Study the full chart
Where price is—and whether the trend supports it
The weekly trend is not active. Price is -26.1% below the Trend Line and sits at 13.1% of its 52-week range. The latest completed week returned -6.7%, after a 12.0% four-week move.
52-week price path
Price vs Trend Line and Fair Value
Price
Trend Line
Fair Value
02 · Volume and demand
Is real participation confirming the move?
Latest weekly volume is 0.3x the 13-week average. Participation is below its recent norm, so price strength is not receiving full volume confirmation.
26-week volume confirmation
Bar height shows volume; colour shows the weekly price direction
30 Jan
6 Feb
13 Feb
20 Feb
27 Feb
6 Mar
13 Mar
20 Mar
27 Mar
3 Apr
10 Apr
17 Apr
24 Apr
1 May
8 May
15 May
22 May
29 May
5 Jun
12 Jun
19 Jun
26 Jun
3 Jul
10 Jul
17 Jul
24 Jul
Up week
Down week
Demand beneath price
Activity pressure and institutional-style signals
These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.
Activity pressure path
Latest 0.0212-week average 0.03
12-week confirmation
Trend active0/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure0/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership0/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.02Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers0No reversal markers
No recent accumulation markers. No reversal markers.
03 · Momentum and leadership
Is performance persistent—and is the stock leading?
Performance is 12.0% over four weeks, -22.8% over 12 weeks, and -47.9% over one year. The current trend has remained active for 0 consecutive weeks.
Performance by holding period
Active trend streak0 weeks
Active weeks in one year2
Trend breadth3.8%
Activity pressure vs relative leadership
Activity pressureRelative leadership
Pressure-1.03Latest activity-pressure read.
Pressure change-1.4%Four-week change in activity pressure.
Leadership-29.65Latest relative-leadership reading.
RS change26.5%Four-week change in relative leadership.
04 · Fundamentals and valuation
Open full factor analysis
What investors are paying for—and the quality behind it
The latest factor snapshot indicates quality ranks weakly versus its universe; growth ranks weakly; valuation is expensive relative to peers.
Factor week 26 Jul 2026
Financial statements through 31 Dec 2025
Field coverage 70%
Model confidence 57%
Relative factor standing
Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.
Overall factor strength2/100Blend of value, momentum, and quality. Underlying universe rank 99; rank 1 is best.
Value12/100Relative valuation strength. Underlying universe rank 89; rank 1 is best.
Quality1/100Profitability and accounting quality. Underlying universe rank 100; rank 1 is best.
Momentum4/100Medium-term price momentum. Underlying universe rank 97; rank 1 is best.
Growth5/100Revenue and earnings growth. Underlying universe rank 96; rank 1 is best.
Quality and valuation are separate questions
A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.
Valuation
How much investors are paying for earnings, sales, and cash flow.
- P/E
- - Price divided by trailing earnings.
- Price / sales
- 4.2x Market value relative to trailing revenue.
- EV / EBITDA
- - Enterprise value relative to operating cash earnings.
- Free-cash-flow yield
- -27.2% Free cash flow as a share of enterprise value.
Business quality
Margins and the return generated on invested capital.
- Gross margin
- 13.3% Gross profit retained from each unit of revenue.
- Operating margin
- -202.6% Operating profit retained from revenue.
- Free-cash-flow margin
- -116.4% Free cash flow generated from revenue.
- Return on invested capital
- -89.9% Operating return generated on invested capital.
Growth and financial strength
Recent business growth and accounting strength.
- Revenue growth
- -39.5% Latest one-year revenue growth.
- EPS growth
- - Latest one-year earnings-per-share growth.
- Free-cash-flow growth
- - Latest one-year free-cash-flow growth.
- Piotroski F-score
- 1/9 Nine-point accounting-strength checklist.
Shareholder return and balance sheet
Cash returned to owners and financial leverage.
- Dividend yield
- - Cash dividends relative to market value.
- Buyback yield
- 0.0% Net share repurchases relative to market value.
- Shareholder yield
- 0.0% Dividend yield plus net buyback yield.
- Net debt / EBITDA
- -0.1x Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment
What other market participants are doing
Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.
Insider activity-
No recent insider transactions are stored for this company.
News sentiment56/100
Weighted news tone is neutral across 19 relevant articles.
5 positive · 13 neutral · 1 negativePatient CapitalQuiet
Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.
No recent buy signal
06 · Catalysts and risk
What can move the shares—and how volatile the path has been
Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.
Next earnings-No event is currently stored.
Options expected move-Nearest-chain priced movement where available.
52-week drawdown-56.6%Distance below the 52-week high.
13-week volatility8.8%Standard deviation of weekly returns.
Weekly gains and losses
Latest 26 completed weeksEach bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.
30 Jan
27 Feb
27 Mar
24 Apr
22 May
19 Jun
24 Jul
Weeks higher9 of 2617 weeks finished lower.
Best week+33.0%Week of 30 Jan.
Worst week-15.8%Week of 6 Feb.
Latest week-6.7%Week of 24 Jul.
Shape of recent returns
Strong gains6
Modest gains3
Flat weeks0
Modest losses5
Sharp losses12
Recent vol8.8%13-week weekly-return volatility.
Base vol9.8%52-week weekly-return volatility.
Up/down split22/30Count of positive and negative weeks in the 52-week window.
Average skew7.7% / -7.0%Average positive week versus average negative week.
07 · Sector and peer context
Is this stock leading—or simply moving with its group?
Sector and industry breadth distinguish company-specific strength from a broad group move.
SectorAU Healthcare
4-week rank23 / 100
Group average1.9%
Trend breadth22.0%
Trend22.0%active weekly trend signals
MD60.0%positive activity pressure
RS29.0%positive relative leadership
Four-week leaders
IndustryAU Medical Distribution
4-week rank1 / 5
Group average6.5%
Trend breadth0.0%
Trend0.0%active weekly trend signals
MD80.0%positive activity pressure
RS0.0%positive relative leadership
Four-week leaders
08 · Evidence and weekly data
The underlying research record
Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.
Weekly tape13/100
Trend, activity pressure, participation, and risk combine to a 13/100 tape read.
Indicator analysis9/100Latest 12-week confirmation: trend 0/12, activity pressure 0/12, relative leadership 0/12.
Activity pressure 0.02; No reversal markers Next-Week ExpectancyNegative 41.68%Next-week expectancy is negative with a 41.68% historical one-week setup read.
Adds short-term historical context without overriding trend, activity, or relative leadership. Factors3/100O'Shaughnessy factor stack blends value, quality, momentum, and confidence.
Buyback Yield rank 54; Small Cap Core rank 86 Patient CapitalQuietActivity-pressure buy-signal evidence highlights potential institutional accumulation windows.
No recent buy signal Sentiment56/100Weighted news tone is neutral across 19 relevant articles.
Cyclopharm (ASX:CYC) Adds 7.14% as Commercial Expansion Strategy Remains on Investors' Radar Insiders50/100No recent insider transaction evidence is stored.
Earnings50/100No stored earnings event is currently attached to this ticker.
| Week | Close | Return | Trend Line | Fair Value | Pressure | Leadership | Volume | Trend |
|---|---|---|---|---|---|---|---|---|
| 24 Jul 2026 | 0.56 AUD | -6.7% | 0.76 AUD | 1.40 AUD | -1.03 | -29.65 | 176.9K | Off |
| 17 Jul 2026 | 0.60 AUD | 14.3% | 0.77 AUD | 1.41 AUD | -1.03 | -25.78 | 1.2M | Off |
| 10 Jul 2026 | 0.53 AUD | 6.1% | 0.78 AUD | 1.42 AUD | -1.19 | -35.89 | 429.7K | Off |
| 3 Jul 2026 | 0.49 AUD | -1.0% | 0.80 AUD | 1.43 AUD | -1.16 | -40.58 | 533.4K | Off |
| 26 Jun 2026 | 0.50 AUD | -11.5% | 0.81 AUD | 1.44 AUD | -1.01 | -40.33 | 5.0M | Off |
| 19 Jun 2026 | 0.56 AUD | -1.7% | 0.82 AUD | 1.45 AUD | -0.94 | -33.76 | 21.1K | Off |
| 12 Jun 2026 | 0.57 AUD | -8.7% | 0.83 AUD | 1.46 AUD | -0.68 | -33.05 | 21.8K | Off |
| 5 Jun 2026 | 0.63 AUD | -11.3% | 0.83 AUD | 1.47 AUD | -0.42 | -25.91 | 353.2K | Off |
| 29 May 2026 | 0.71 AUD | -2.7% | 0.83 AUD | 1.48 AUD | -0.32 | -18.32 | 13.9K | Off |
| 22 May 2026 | 0.73 AUD | -9.3% | 0.83 AUD | 1.49 AUD | -0.35 | -16.28 | 263.2K | Off |
| 15 May 2026 | 0.81 AUD | -4.7% | 0.83 AUD | 1.49 AUD | -0.48 | -8.44 | 268.3K | Off |
| 8 May 2026 | 0.84 AUD | 16.6% | 0.82 AUD | 1.50 AUD | -0.58 | -6.02 | 273.6K | Off |
| 1 May 2026 | 0.72 AUD | 2.8% | 0.82 AUD | 1.51 AUD | -0.62 | -20.24 | 130.0K | Off |
| 24 Apr 2026 | 0.70 AUD | -2.1% | 0.82 AUD | 1.52 AUD | -0.57 | -23.82 | 108.0K | Off |
How to use this report
This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.